Daewon Pharmaceutical to Resume Pouch Supply of Antitussive "Previtus Suspension" Next Month

Production Halted in 2024 Due to Raw Material Shortages
Resumption of Manufacturing Decided in Response to Field Requests

Daewon Pharmaceutical announced on September 28 that it has resumed production of the pouch formulation of its antitussive and expectorant "Previtus Suspension" and will begin supplying it normally from October.

Previtus Suspension is an original formulation antitussive with levocloperastine as its main ingredient. It acts on both the central and peripheral nervous systems to alleviate coughing. Daewon Pharmaceutical has supplied the product in two forms: a pouch formulation for adult patients and a bottle (vial) formulation for pediatric patients.

Production of the pouch formulation was temporarily suspended in 2024 due to difficulties in sourcing raw materials amid an increase in respiratory patients. At that time, Daewon Pharmaceutical prioritized the production of the pediatric bottle formulation, which had limited alternatives, over the pouch type, as it was difficult to supply both forms stably at the same time.

However, even after that, the medical community has continually requested the resumption of supply for the original levocloperastine formulation. With ongoing demand from the medical field and recent stabilization of raw material supply, the company decided to resume production of the pouch formulation.

Daewon Pharmaceutical expects that, once the supply of the adult pouch formulation is normalized starting next month, it will provide doctors with greater prescription options and improve patient convenience when taking the medication.

A company representative stated, "Although we temporarily halted production of the pouch formulation due to issues with raw material supply, we continuously received requests from the medical field to resume supply. Since the decision to resume production was made in response to those requests, we will continue to strive to stably supply products needed by healthcare professionals and patients."

This content was produced with the assistance of AI translation services.